NCT05614739 2026-04-20
FORAGER-1
Eli Lilly and Company
Phase 1 Recruiting
Clinical Trials
10 trialsNCT07421700 2026-04-20
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Recruiting
NCT07475806 2026-04-15
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Astellas Pharma Inc
Phase 2 Recruiting
NCT06011954 2026-04-14
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Astellas Pharma Inc
Recruiting
NCT07232602 2026-04-13
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07484022 2026-04-07
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT07287995 2026-04-01
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT06862219 2026-03-06
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Astellas Pharma Inc
Phase 4 Recruiting
NCT06493552 2025-04-03
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Phase 2/3 Recruiting